The toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 974-980

  Holzinger, Dirk ^a   Frosch, Michael ^a   Kastrup, Astrid ^a   Prince, Femke H M ^b   Otten, Marieke H ^b   Van Suijlekom Smit, Lisette W A ^b   Ten Cate, Rebecca ^c   Hoppenreijs, Esther P A H ^d   Hansmann, Sandra ^e   Moncrieffe, Halima ^f   Ursu, Simona ^f   Wedderburn, Lucy R ^f   Roth, Johannes ^a   Foell, Dirk ^a   Wittkowski, Helmut ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INTERLEUKIN 1; METHOTREXATE; METHYLPREDNISOLONE; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ACTIVE JOINT COUNT; ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; ARTICLE; CHILD; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RECURRENCE RISK; RELAPSE; REMISSION; RISK ASSESSMENT; SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SYSTEMIC DISEASE; SYSTEMIC ONSET JUVENILE RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CALGRANULIN B; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METHOTREXATE; METHYLPREDNISOLONE; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84860919270     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200598     Document Type: Article

References (28)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:883-91.
3. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:628-37. (Pubitemid 30394955)
4. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-502. (Pubitemid 27154966)
5. Roth J, Vogl T, Sorg C, et al. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003;24:155-8. (Pubitemid 36412096)
6. Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005;105:2955-62. (Pubitemid 40446292)
7. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998;160:1427-35. (Pubitemid 28093444)
8. Niki Y, Yamada H, Seki S, et al. Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 2001;107:1127-35. (Pubitemid 32422909)
9. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71. (Pubitemid 39643922)
10. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.
11. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
12. Ruperto N, Ravelli A, Falcini F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998;57:38-41. (Pubitemid 28175218)
13. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
14. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
15. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4. (Pubitemid 39453253)
16. Brunner HI, Lovell DJ, Finck BK, et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64. (Pubitemid 34493514)
17. van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008;67:1750-8.
18. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042-9. (Pubitemid 47517513)
19. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010;16:713-17.
20. de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007;66:589-98. (Pubitemid 46707126)
21. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58:1505-15. (Pubitemid 351705940)
22. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8. (Pubitemid 351281262)
23. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86. (Pubitemid 40664091)
24. Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:1228-9.
25. Wulffraat NM, Haas PJ, Frosch M, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis 2003;62:236-41. (Pubitemid 36238087)
26. de Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
27. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008;371:998-1006. (Pubitemid 351389534)
28. de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009;10:52.